Are cultured mesenchymal stromal cells an option for immunomodulation in transplantation?

Vijay S Gorantla,Jan A Plock,Jonas T Schnider,Riccardo Schweizer

doi:10.3389/fimmu.2013.00041

Abstract

Are cultured mesenchymal stromal cells an option for immunomodulation in transplantation?

Highlights

Mesenchymal stromal cells (MSCs) are under investigation for clinical application
These results confirm that, in addition to a need for greater understanding of their functional and immunologic characteristics, there is a need to investigate the migratory properties of cultured MSCs in circulation prior to clinical implementation
The present study supports the findings from Fischer et al (2009), who have described a first-pass effect in the lung capillaries for MSCs

Summary

Introduction

Mesenchymal stromal cells (MSCs) are under investigation for clinical application. Despite approval by the United States Food and Drug Administration for MSC use in pediatric steroid-refractory acute GvHD after allogeneic hematopoietic stem cell transplantation (Parekkadan and Milwid, 2010) uncertainty about the fate of MSCs after infusion remains far. Eggenhofer et al (2012) presented evidence in a mouse model that cultured bone-marrow derived MSCs are entrapped in the lungs after intravenous infusion. This study elegantly could show a dependency of MSCs and their ability to pass the lung filter on size and surface antigens.

Results

Conclusion